Lilly, Hospira Settle Gemzar Patent Fight

Law360, Los Angeles (August 10, 2011, 4:03 PM EDT) -- Eli Lilly & Co. and Hospira Inc. said Tuesday they had reached a settlement in Hospira’s Illinois suit seeking a declaration that its planned generic version of cancer drug Gemzar did not infringe a Lilly patent.

The parties' stipulation asking U.S. District Judge Milton I. Shandur to dismiss the case ushers in the end of U.S. litigation in an intellectual property fight over the ovarian, breast, lung and pancreatic cancer treatment that has sparked lawsuits between the companies in five countries.

Hospira filed the U.S. complaint...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.